STA
AMED

Summit Trail Advisors’s Amedisys AMED Stock Holding History

Summit Trail Advisors’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,019
Closed -$592K – 1346
2025
Q2 		$592K Buy
+6,019
New +$569K 0.01% 665
2024
Q4 		– Sell
-3,705
Closed -$358K – 415
2024
Q3 		$358K Buy
+3,705
New +$362K 0.01% 494

Other funds holding AMED

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MCI
MRP Capital Investments Alpharetta, Georgia $115M AUM 48.08% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Summit Trail Advisors's AMED Position: Q3 2025 in Review

Summit Trail Advisors sold out of Amedisys (AMED) in Q3 2025, closing a stake of 6,019 shares — an estimated $592K sold.

Summit Trail Advisors first reported a position in AMED in Q3 2024 and held it in 2 quarters. The position peaked at $592K in Q2 2025. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • Summit Trail Advisors reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • Summit Trail Advisors sold 6,019 Amedisys shares in Q3 2025, an estimated $592K.
  • Summit Trail Advisors first reported a position in Amedisys in Q3 2024 and held it in 2 quarters.
  • Summit Trail Advisors's Amedisys position peaked at $592K in Q2 2025.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on Summit Trail Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.